There are currently 1537 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/23/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Ulcerative Colitis
Register for Updates
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
NCT05924477
Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
Conditions: Glaucoma
Register for Updates
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
NCT05785754
Recruiting
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200
Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
06/23/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Register for Updates
Remote Sputum Collection in Cystic Fibrosis
NCT06950892
Recruiting
Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection det... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Cystic Fibrosis, Infections
Register for Updates
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Endometrial Cancer
Register for Updates
Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure
NCT06364644
Recruiting
This study aims to determine whether a 6-month multilevel intervention involving problem-solving training, exercise training and support from community health workers is more effective in improving outcomes for individuals with low socioeconomic status, type 2 diabetes, obesity, and early cardiac dysfunction than receiving education and access to a community exercise facility.
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
06/23/2025
Locations: Johns Hopkins Center for Health Equity, Baltimore, Maryland
Conditions: Type2diabetes, Heart Failure, Obesity
Register for Updates
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NCT06552741
Recruiting
Background: People who will participate in research studies need to undergo proper screening, evaluation, and assessment (SEA). SEA helps keep those who participate in studies safe. It also helps ensure accurate study results. The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) wants to screen people with alcohol and/or substance use disorders (ASUD) as well as people without ASUD for ongoing studies at NIDA in Baltimore, MD Objective: To screen people with or withou... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/21/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Substance Use Disorder, Alcohol Use Disorder
Register for Updates
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517
Recruiting
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/20/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Hemolytic Disease of the Fetus and Newborn
Register for Updates
Global Patient Registry of Inherited Retinal Diseases
NCT05957276
Recruiting
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
06/20/2025
Locations: John Hopkins Hospital, Baltimore, Maryland
Conditions: Inherited Retinal Diseases
Register for Updates
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT06233942
Recruiting
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
NCT06742996
Recruiting
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Register for Updates